

This listing of claims will replace all prior versions, and listings, of claims in the application:

**LISTING OF CLAIMS**

Claim 1. (Currently Amended) A pharmaceutical composition ~~cytochrome P450 3A~~  
~~(CYP3A)~~ inhibitor comprising a cytochrome P450 3A (CYP3A) inhibitor, a drug that undergoes  
a first-pass effect in a patient, and at least one pharmaceutically acceptable excipient; wherein  
said CYP3A inhibitor is a free base or pharmacologically acceptable salt of at least one  
compound selected from the group consisting of α-naphthoflavone, β-naphthoflavone, baicalein,  
catechin, 3-phenylpropyl acetate, formononetin, lauryl alcohol, luteolin, luteolin-7-glycoside,  
nordihydroguaiaretic acid, and swertiamarin, and wherein said CYP3A inhibitor inhibits CYP3A  
enzymatic activity.

Claim 2. (Cancelled)

Claim 3. (Cancelled)

Claim 4. (Cancelled)

Claim 5. (Currently Amended) A method for inhibiting cytochrome P450 3A (CYP3A)  
enzymatic activity in a patient comprising: orally administering a CYP3A inhibitor ~~according to~~  
~~claim 1~~ to said patient in need thereof and then, optionally administering another drug that  
undergoes a first-pass effect; wherein said CYP3A inhibitor is a free base or pharmacologically

acceptable salt of at least one compound selected from the group consisting of  $\alpha$ -naphthoflavone,  
 $\beta$ -naphthoflavone, baicalein, catechin, 3-phenylpropyl acetate, formononetin, lauryl alcohol,  
luteolin, luteolin-7-glycoside, nordihydroguaiaretic acid, and swertiamarin.

Claim 6. (cancelled)

Claim 7. (Currently Amended) The method according to claim 5, wherein said pharmaceutical composition ~~CYP3A inhibitor~~ is administered orally to said patient with food or in the form of a capsule or tablet.

Claim 8. (Previously Presented) The method according to claim 5, wherein said CYP3A inhibitor is co-administered with a drug that undergoes a first-pass effect in said patient.

Claim 9. (Previously Presented) The method according to claim 8, wherein said drug that undergoes a first-pass effect and said CYP3A inhibitor are co-administered orally.

Claim 10. (Previously Presented) The method according to claim 8, wherein said drug that undergoes a first-pass effect is one selected from the group consisting of erythromycin, felodipine, troleandomycin, nifedipine, cyclosporin, FK506, teffenadine, tamoxifen, lidocaine, triazolam, dapsone, diltiazem, lovastatin, simvastatin, quinidine, ethylestradiol, testosterone, midazolam, and alfentanil.

Appl. No.: 10/080,043  
Response dated April 25, 2006  
Reply to Office Action of January 4, 2006

Claim 11. (Currently Amended) The method according to claim 8, wherein said ~~CYP3A inhibitor is catechin, and~~ wherein said drug that undergoes a first-pass effect is simvastatin.

Claims 12-25 (Cancelled)

Claim 26 (new) The pharmaceutical composition according to claim 1, wherein said drug that undergoes a first-pass effect is one selected from the group consisting of erythromycin, felodipine, troleandomycin, nifedipine, cyclosporin, FK506, teffenadine, tamoxifen, lidocaine, triazolam, dapsone, diltiazem, lovastatin, simvastatin, quinidine, ethylestradiol, testosterone, midazolam, and alfentanil.